Compare Biogen Inc (BIIB) vs Cigna Corp (CI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Cigna Corp — how do they compare? Biogen Inc trades at $206.24 (market cap $30.13B), while Cigna Corp trades at $273.93 (market cap $73.56B). The key difference: Cigna Corp is far larger — about 2.4× Biogen Inc's market cap, and Cigna Corp pays a 2.24% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | CI | |
|---|---|---|
Market Cap | $30.13B | $73.56B |
Sector | Health | Health |
52-Week High | $216.63 | $311.00 |
52-Week Low | $128.93 | $244.41 |
Enterprise Value | $37.20B | $98.27B |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
Cigna (CI) trades at $278.40, down 1.45% on the day, with a bearish technical signal but strong fundamentals including a P/E of 11.51 and ROE of 15.49%. Recent Q2 2026 earnings beat expectations at $7.78 per share, and the company raised its full-year EPS guidance. The stock is supported by consistent dividend payments and robust cash flow from operations of $9.60 billion in 2025.
The outlook is positive with a consensus price target of $338.90, implying 22% upside. Key opportunities include steady earnings growth and capital returns, while risks involve healthcare cost pressures and competitive dynamics. Analyst sentiment is strongly bullish with 73.68% buy ratings, though technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →
